73 results about "Cartilage Diseases" patented technology

A joint support and subchondral support system for providing structural and dampening support to damaged subchondral bone in generalized or discrete arthritis includes a contoured, porous plate having a variable shaped inner surface, outer surface, and peripheral surface of variable thickness extending between the inner surface and the outer surface, suitable for insertion within the subchondral bone. The inner surface, outer surface and peripheral surface each have a concave portion and a convex portion. A guide pin hole or slot is located within the contoured, porous plate to aid in insertion and placement of the plate over at least one corresponding guide pin within the subchondral bone. The joint support and subchondral support system of the present invention is applicable to many parts of the joint as any area with cartilage disease has an adjoining subchondral component.

The invention provides a compound betamethasone suspension injection, which is a compound preparation composed of low-solubility betamethasone dipropionate and high-solubility betamethasone sodium phosphate. Long-lasting, it can be used for the treatment of musculoskeletal and cartilage tissue diseases, allergic diseases, skin diseases, collagen diseases, tumors and other clinical diseases.

The invention belongs to the technical field of medicine; in order to solve the problem that no efficient and safe cartilage siRNA delivery system is provided for limiting application of RNAi in treating cartilage diseases, the invention provides a cartilage siRNA liposome delivery system and a preparation method of the delivery system. The delivery system consists of lipidosome, a lipidosome modifier and a small nucleic acid drug, wherein the lipidosome is phosphatidylcholine, cholesterol or Dlin-KC2-DMA; the lipidosome modifier is a polyethylene glycol lipid conjugate; and the small nucleic acid drug is Ihh siRNA. According to the invention, a liposome nano based cartilage RNA interference delivery system is modified, and the formed composite has positive charges, is safe and small in volume, and can be distributed in a full-lamellar cartilage tissue. Carrier experiments verify that siRNA can be delivered into cartilage cells to successful knock out corresponding genes inside the cartilage cells, therefore a bottleneck of gene knockout in the cartilage tissue is broken through; and the siRNA, as a target gene, can be used for treating PTOA (post-traumatic osteoarthritis).

The invention discloses new application of melatonin, fills the technical blanks in the prior art, and discloses the application of the melatonin in the preparation of drugs for promoting mesenchymal stem cell chondrogenic differentiation, the application of the melatonin in the preparation of drugs for treatment of joint diseases, and the application of the melatonin in the preparation of drugs for treatment of cartilage diseases. The application introduces two representative proinflammatory cytokines including IL-1 beta (Interleukin-1 beta) and TNF-alpha (tumor necrosis factor-alpha), creates two in-vitro arthritis cell models for studying to determine mesenchymal stem cell in-vitro chondrogenic differentiation promoted by the melatonin and a mechanism thereof, and establishes a foundation for further application of the melatonin in the preparation of the drugs for promoting the mesenchymal stem cell chondrogenic differentiation, in the preparation of the drugs for treatment of the joint diseases, and in the preparation of the drugs for treatment of the cartilage diseases.

A composition for regenerative treatment of cartilage disease, which comprises a PDE4 inhibitor as an active ingredient, specifically a composition comprising a PDE4 inhibitor and a biocompatible and biodegradable polymer is provided, which composition, when formulated into a form suited to administer locally to affected cartilage region, such as microsphere preparation, can provide a pharmaceutical composition showing an excellent effect in regenerative treatment of cartilage.

The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries.

The invention relates to an icariin and hyaluronic acid composition, a method for preparing the same and application of the icariin and hyaluronic acid composition. The icariin and hyaluronic acid composition, the method and the application have the advantages that the icariin and hyaluronic acid composition can be used for preparing medicines for treating cartilage diseases and can be particularly used for preparing injection for joint cavities, accordingly, the shortcoming of limitation of single hyaluronic acid treatment can be overcome, the application range can be expanded, and adverse reaction can be reduced; effects of covering and protecting the surfaces of cartilage can be enhanced by the aid of pharmacological effects of icariin on cartilage cells; the icariin and hyaluronic acid composition can act on synovial cells, synthesis of autologous macromolecular hyaluronic acid can be promoted, and accordingly the purposes of nourishing the cartilage, lubricating the joint cavities, relieving pain, improving the daily activity ranges and the joint activity ranges of patients and the like can be achieved; the icariin and hyaluronic acid composition can act on the cartilage cells, accordingly, the viability of the cartilage cells can be enhanced, secretion of active substances such as type II collagen of the cartilage cells and mucopolysaccharide can be promoted, and nourishing, lubricating, regenerating and functional reconstruction effects and the like can be jointly realized; knowledge on traditional Chinese medicine injection can be changed, the adverse reaction can be reduced to a great extent, curative effects of hyaluronic acid and the traditional Chinese medicine injection can be improved, and the application ranges of the hyaluronic acid and the Chinese medicine injection can be expanded.

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

The invention belongs to the technical field of biological medicine, and provides application of a nitrogen-doped carbon quantum dot delivery system in cartilage tissue in order to solve the problem that in current cartilage disease research, a compact structure on the surface layer of the cartilage tissue cannot be effectively penetrated to enter deep cells of the cartilage tissue. The application comprises the following steps of dissolving o-phenylenediamine in deionized water, and magnetically stirring at room temperature to form a clear and transparent solution; heating the solution to 180 DEG C in a high-pressure reaction kettle, reacting for 12 hours, and naturally cooling to room temperature to obtain carbon quantum dots; filtering by using a 0.22 m filter membrane of the carbon quantum dots, and dialyzing for 24 hours by using a dialysis bag with the molecular weight cut-off of 3500 Da; and freeze-drying, and dissolving in deionized water to obtain the nitrogen-doped carbon quantum dot delivery system. The nitrogen-doped carbon quantum dot delivery system is good in biocompatibility, high in targeting property, high in transfection efficiency, relatively small in size and capable of smoothly passing through a compact structure on the surface of the cartilage tissue, and can become an excellent cartilage tissue disease diagnosis method; and the system can smoothly enter the cartilage cells through the superficial compact structure of the cartilage tissue, and great clinical treatment significance is achieved.

The applications and medical devices of Midkine in the field of biotechnology are described in this invention. This invention describes the applications of the protein as follow in (a) or (b) in preparing drugs for promoting cartilage growth or treating cartilage diseases, the protein as a growth factor for promoting chondrocyte proliferation, or medical devices containing this protein: (a) the protein whose amino acid sequence is shown as SEQ ID NO.1; (b) the proteins whose amino acid sequence have at least 60% homology comparing with amino acid sequence described in (a) and have activity for promoting proliferation of chondrocyte. The protein described in this invention promotes proliferation of three types of chondrocytes and is used for preparing drugs for treating cartilage disease. It may provide new therapy for treating cartilage diseases clinically, and new technology for expansion of chondrocytes in vitro for cartilage tissue engineering.

Use of a compound of Formula 1 for inducing differentiation of mesenchymal stem cells to chondrocytes, and a pharmaceutical composition for treating a cartilage disease, which includes chondrocytes in which differentiation from mesenchymal stem cells is induced by the compound of Formula 1, are provided. Differentiation of the mesenchymal stem cells treated with the compound of Formula 1 to chondrocytes is specifically induced, and thus the compound can be used to effectively treat a cartilage disease such as arthritis, cartilage damage, and a cartilage defect.

The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.